Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Task Force Changes Stance on Value of PSA Test

May 21st 2018

The US Preventive Services Task Force has concluded that there is a small mortality benefit associated with prostate-specific antigen-based prostate cancer screening for men aged 55 to 69 years, a departure from earlier guidance.

Study Findings Complicate the Paradigm for Hormone-Sensitive Prostate Cancer

May 21st 2018

Data from recent trials in metastatic hormone-sensitive prostate cancer have demonstrated the heterogeneous nature of prostate cancer and its subtypes, highlighting the importance of a more cautious approach in choosing therapies for patients.

Dr. Choyke on Combining Imaging Techniques in Prostate Cancer

May 14th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the combination of imaging techniques in prostate cancer.

Focusing on Risk Stratification in Prostate Cancer

May 14th 2018

The National Comprehensive Cancer Network has overhauled its guidelines for managing prostate cancer with a greater emphasis on risk stratification for molecular testing and therapy choices.

Expert Discusses Radiation Techniques, Genomic Testing in Prostate Cancer

May 11th 2018

James B. Yu, MD, discusses techniques with radiation therapy, potential roadblocks, and the importance of genomic testing in treating patients with prostate cancer.

Novel Radionuclide Treatment Shows Promise in mCRPC

May 11th 2018

Radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 nearly doubled median PSA progression-free survival in men with progressive metastatic castrate-resistant prostate cancer compared with previous results with radium-223.

Dr. Mark on the Use of Degarelix in Men With Prostate Cancer

May 8th 2018

James Ryan Mark, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the use of degarelix (Firmagon) in the treatment of men with prostate cancer.

Dr. Godwin on Ongoing Clinical Trials for Men With Prostate Cancer

May 8th 2018

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses ongoing trials for men with prostate cancer.

Dr. Trabulsi Defines Locally Advanced Prostate Cancer

May 7th 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

The Case for Platinum Therapy in Prostate Cancer

May 2nd 2018

The arsenal of therapeutic options for men with castration-resistant prostate cancer has steadily grown as ongoing research uncovers more about prostate cancer biology and resistance mechanisms.

Dr. Choyke on Advancements in Imaging for Prostate Cancer

April 30th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses advances in imaging for prostate cancer.

Dr. Den Discusses the Future of Prostate Cancer Research

April 25th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.

Dr. Yu on the Importance of a Genetic Counselor in Prostate Cancer

April 14th 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

Treatment Developments Shaking Up Landscape for Nonmetastatic CRPC

April 13th 2018

Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.

Ongoing Trial to Determine Role of Degarelix in Lowering Cardiovascular AEs in Prostate Cancer

April 12th 2018

The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.

Dr. Hussain Discusses PARP Inhibitors in Prostate Cancer

April 10th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses PARP inhibitors in the treatment of patients with prostate cancer.

Dr. Kelly on the Importance of Local Control in Locally Advanced Prostate Cancer

April 10th 2018

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, director, Division of the Solid Tumor Oncology, Sidney Kimmel Cancer Center, discusses the evolution of local control in locally advanced prostate cancer.

Dr. Den Discusses Bone Metastases in Prostate Cancer

April 4th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone metastases in prostate cancer.

Dr. Yu on Emerging Standards in Radiation for Prostate Cancer

April 2nd 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses emerging standards in radiation for the treatment of patients with prostate cancer.

Multimodal Approaches Emerging in Locally Advanced Prostate Cancer

April 1st 2018

Edouard J. Trabulsi, MD, discusses emerging multimodal treatment approaches for patients with locally advanced prostate cancer.